Oppenheimer lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $56 and keeps an Outperform rating on the shares. On Tuesday, the company reported Q2 results, highlighting updated clinical data for CRB-701 to be presented at ESMO in October for the Nectin-4 targeting ADC, the firm notes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals Reports Q2 2025 Financials and Updates
- Corbus Pharmaceuticals: Promising Outlook with Key Data Releases and Strong Financial Position
- Corbus Pharmaceuticals Receives FDA Fast Track Designation
- Corbus Pharmaceuticals reports Q2 EPS ($1.44), consensus ($1.33)
- Corbus Pharmaceuticals transferred with Buy rating at B. Riley